Detalhe da pesquisa
1.
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma.
Cancer Res Commun;
2(5): 307-315, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36875713
2.
Clinico-laboratory pertinences and management of relapsed and refractory.
J BUON;
26(3): 1165-1168, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34268985
3.
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
Blood Adv;
4(17): 4136-4146, 2020 09 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32886753
4.
Bringing Global Hematology Research to the Forefront.
Blood Adv;
2024 May 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38739717